Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and Apoplexy

rosiglitazone has been researched along with Apoplexy in 28 studies

Research

Studies (28)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's10 (35.71)29.6817
2010's18 (64.29)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, ZA; Huang, TT; Li, PY; Li, Y; Lu, BW; Wen, DX; Xuan, W; Yu, WF; Zhang, YM; Zhou, NY; Zhu, ZY1
Liu, J; Wang, LN3
Bach, RG; Brooks, MM; Donner, TW; Frye, RL; Garber, A; Genuth, S; Kelsey, SF; Kennedy, L; Lombardero, M; Monrad, ES; Pop-Busui, R1
Bigelow, R; Burns, S; Dickerson, S; Hafley, G; Home, PD; Komajda, M; Lopes, RD; Mahaffey, KW; McMurray, J; Newby, LK; Tourt-Uhlig, S; White, J2
Chen, PC; Chen, RC; Hsu, CY; Lu, CJ; Muo, CH; Sun, Y1
Ballesteros, I; Corbí, ÁL; Cuartero, MI; Hamilton, JA; Lizasoain, I; Moraga, A; Moro, MA; Nombela, F; Vivancos, J1
Dangi-Garimella, S1
Calingaert, B; Margulis, AV; Perez-Gutthann, S; Pladevall, M; Riera-Guardia, N; Varas-Lorenzo, C1
Levin, R; Setoguchi, S; Solomon, DH; Winkelmayer, WC1
Divine, G; Habib, ZA; Havstad, SL; Krajenta, R; Lanfear, DE; Pladevall, M; Tang, J; Tzogias, L; Wells, K; Williams, LK1
Ballesteros, I; Caso, JR; Fernández-López, D; Hurtado, O; Lizasoain, I; Moro, MA; Nombela, F; Pereira, MP; Pradillo, JM; Serena, J; Sobrado, M; Vivancos, J1
Retnakaran, R; Zinman, B1
Beck-Nielsen, H; Curtis, PS; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; McMurray, JJ; Pocock, SJ1
Chen, YC; Fong, WH; Lin, TN; Tsai, HD; Wu, JS1
Asghari, S; Carpentier, AC; Courteau, J; Vanasse, A1
Tanne, JH1
Ali, F; Graham, DJ; Kelman, JA; MaCurdy, TE; Ouellet-Hellstrom, R; Sholley, C; Worrall, C1
Blankenship, DA; Gamboa, J; Hilow, E; Karl, M; Landreth, GE; Niemi, JP; Sundararajan, S1
Gallagher, AM; Leufkens, HG; Seabroke, S; Smeeth, L; van Staa, TP1
Atar, D; Serebruany, VL1
Allahtavakoli, M; Djahanguiri, B; Parviz, M; Sadr, SS; Shabanzadeh, AP1
Clancy, P; Golledge, J; Mangan, S1
Ahn, KO; Bang, BK; Choi, BS; Kim, J; Kim, JY; Kim, SH; Kim, YS; Li, C; Lim, SW; Yang, CW; Yang, HJ1
Allahtavakoli, M; Pourshanazari, A; Roohbakhsh, A; Shabanzadeh, A1

Reviews

5 review(s) available for rosiglitazone and Apoplexy

ArticleYear
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack.
    The Cochrane database of systematic reviews, 2017, 12-02, Volume: 12

    Topics: Cardiovascular Diseases; Carotid Artery Diseases; Humans; Hypoglycemic Agents; Insulin Resistance; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Proteasome Endopeptidase Complex; Randomized Controlled Trials as Topic; Recurrence; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones; Ubiquitin

2017
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.
    The Cochrane database of systematic reviews, 2014, Jan-08, Issue:1

    Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones

2014
Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack.
    The Cochrane database of systematic reviews, 2015, Oct-29, Issue:10

    Topics: Cardiovascular Diseases; Humans; Hypoglycemic Agents; Ischemic Attack, Transient; Myocardial Infarction; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Rosiglitazone; Secondary Prevention; Stroke; Thiazolidinediones

2015
Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies.
    BMC cardiovascular disorders, 2016, Jan-15, Volume: 16

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Myocardial Infarction; Observational Studies as Topic; Pioglitazone; Risk Factors; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones

2016
Anti-apoptotic actions of PPAR-gamma against ischemic stroke.
    Molecular neurobiology, 2010, Volume: 41, Issue:2-3

    Topics: 14-3-3 Proteins; Animals; Apoptosis; bcl-Associated Death Protein; Brain Ischemia; Humans; Hypoglycemic Agents; Ligands; PPAR gamma; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Rosiglitazone; Stroke; Thiazolidinediones

2010

Trials

2 trial(s) available for rosiglitazone and Apoplexy

ArticleYear
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
    Circulation, 2013, Aug-20, Volume: 128, Issue:8

    Topics: Aged; Angioplasty; Comorbidity; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Retrospective Studies; Risk Factors; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome

2013
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
    Lancet (London, England), 2009, Jun-20, Volume: 373, Issue:9681

    Topics: Administration, Oral; Angina, Unstable; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Drug Utilization; Female; Fractures, Bone; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Neoplasms; Prospective Studies; Rosiglitazone; Sex Factors; Stroke; Sulfonylurea Compounds; Thiazolidinediones

2009

Other Studies

21 other study(ies) available for rosiglitazone and Apoplexy

ArticleYear
Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
    CNS neuroscience & therapeutics, 2019, Volume: 25, Issue:12

    Topics: Anilides; Animals; Anti-Inflammatory Agents; Blood-Brain Barrier; Hypoglycemic Agents; Infarction, Middle Cerebral Artery; Injections, Intraperitoneal; Intracranial Hemorrhages; Lectins, C-Type; Male; Mannose Receptor; Mannose-Binding Lectins; Mice; Mice, Inbred C57BL; Nitric Oxide Synthase Type II; Plasminogen Activators; PPAR gamma; Receptors, Cell Surface; Rosiglitazone; Stroke; Tissue Plasminogen Activator

2019
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct.
    American heart journal, 2013, Volume: 166, Issue:2

    Topics: Follow-Up Studies; Humans; Hypoglycemic Agents; Mortality; Myocardial Infarction; Randomized Controlled Trials as Topic; Research Design; Rosiglitazone; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration

2013
Results of a reevaluation of cardiovascular outcomes in the RECORD trial.
    American heart journal, 2013, Volume: 166, Issue:2

    Topics: Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemic Agents; Mortality; Myocardial Infarction; Randomized Controlled Trials as Topic; Research Design; Rosiglitazone; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration

2013
Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Cerebrovascular diseases (Basel, Switzerland), 2013, Volume: 36, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Stroke; Thiazolidinediones; Young Adult

2013
N2 neutrophils, novel players in brain inflammation after stroke: modulation by the PPARγ agonist rosiglitazone.
    Stroke, 2013, Volume: 44, Issue:12

    Topics: Brain; Encephalitis; Infarction, Middle Cerebral Artery; Neuroprotective Agents; Neutrophils; PPAR gamma; Rosiglitazone; Stroke; Thiazolidinediones

2013
In brief: rosiglitazone (Avandia) unbound.
    The Medical letter on drugs and therapeutics, 2014, Feb-03, Volume: 56, Issue:1435

    Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Assessment; Risk Factors; Rosiglitazone; Stroke; Thiazolidinediones

2014
The Yin and the Yang of CV risks in patients with diabetes.
    The American journal of managed care, 2014, Volume: 20, Issue:8 Spec No.

    Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration

2014
Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy.
    Archives of internal medicine, 2008, Nov-24, Volume: 168, Issue:21

    Topics: Aged; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Pioglitazone; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome

2008
Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
    Pharmacoepidemiology and drug safety, 2009, Volume: 18, Issue:6

    Topics: Acute Disease; Cardiovascular Diseases; Cohort Studies; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Disease Progression; Drug Therapy, Combination; Female; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Proportional Hazards Models; Retrospective Studies; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome

2009
Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2009, Mar-25, Volume: 29, Issue:12

    Topics: Animals; Arachidonate 5-Lipoxygenase; Brain; Brain Infarction; Infarction, Middle Cerebral Artery; Leukotriene B4; Lipoxins; Mice; Neuroprotective Agents; PPAR gamma; Rats; Rosiglitazone; Stroke; Thiazolidinediones

2009
Thiazolidinediones and clinical outcomes in type 2 diabetes.
    Lancet (London, England), 2009, Jun-20, Volume: 373, Issue:9681

    Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Myocardial Infarction; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones

2009
Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients.
    Diabetes & vascular disease research, 2009, Volume: 6, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus; Drug Prescriptions; Heart Failure; Hospitalization; Humans; Hypoglycemic Agents; Logistic Models; Myocardial Infarction; Odds Ratio; Quebec; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome

2009
GlaxoSmithKline denies it has settled thousands of lawsuits over rosiglitazone (Avandia).
    BMJ (Clinical research ed.), 2010, Jun-07, Volume: 340

    Topics: Compensation and Redress; Drug Industry; Humans; Hypoglycemic Agents; Myocardial Infarction; Rosiglitazone; Stroke; Thiazolidinediones

2010
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.
    JAMA, 2010, Jul-28, Volume: 304, Issue:4

    Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic Agents; Incidence; Male; Medicare Part D; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk; Rosiglitazone; Stroke; Thiazolidinediones; United States

2010
Extension of the neuroprotective time window for thiazolidinediones in ischemic stroke is dependent on time of reperfusion.
    Neuroscience, 2010, Oct-27, Volume: 170, Issue:3

    Topics: Animals; Behavior, Animal; Blood Pressure; Brain; Brain Ischemia; Cell Adhesion Molecules; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Infarction, Middle Cerebral Artery; Leukocytes; Male; Neuroprotective Agents; Pioglitazone; Rats; Rats, Wistar; Regional Blood Flow; Reperfusion; Rosiglitazone; Stroke; Thiazolidinediones

2010
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Diabetes Complications; Diabetes Mellitus; Female; Heart Failure; Hospitalization; Humans; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Risk; Rosiglitazone; Stroke; Thiazolidinediones; Treatment Outcome

2011
Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials--common patterns in TRITON, RECORD, and PLATO?
    Thrombosis and haemostasis, 2012, Volume: 108, Issue:3

    Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Judgment; Metformin; Multicenter Studies as Topic; Myocardial Infarction; Observer Variation; Outcome Assessment, Health Care; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Process Assessment, Health Care; Randomized Controlled Trials as Topic; Rosiglitazone; Stroke; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Ticagrelor

2012
Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume and neurological deficits in an embolic model of stroke.
    Clinical and experimental pharmacology & physiology, 2006, Volume: 33, Issue:11

    Topics: Animals; Behavior, Animal; Brain Edema; Brain Infarction; Dose-Response Relationship, Drug; Fibrinolytic Agents; PPAR gamma; Rats; Rosiglitazone; Stroke; Thiazolidinediones; Time Factors

2006
Effects of peroxisome proliferator-activated receptor ligands in modulating tissue factor and tissue factor pathway inhibitor in acutely symptomatic carotid atheromas.
    Stroke, 2007, Volume: 38, Issue:5

    Topics: Aged; Aged, 80 and over; Carotid Stenosis; Female; Fenofibrate; Humans; Ischemic Attack, Transient; Ligands; Lipoproteins; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Signal Transduction; Stroke; Thiazolidinediones; Thromboplastin

2007
Renoprotective effects of rosiglitazone in stroke-prone spontaneously hypertensive rats.
    Kidney & blood pressure research, 2007, Volume: 30, Issue:4

    Topics: Animals; Blood Pressure; Hypertension; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rosiglitazone; Stroke; Thiazolidinediones

2007
Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats.
    Basic & clinical pharmacology & toxicology, 2007, Volume: 101, Issue:5

    Topics: Animals; Behavior, Animal; Blood Coagulation; Brain; Cerebral Infarction; Dimethyl Sulfoxide; Dizocilpine Maleate; Drug Synergism; Drug Therapy, Combination; Hypnotics and Sedatives; Intracranial Embolism; Neuroprotective Agents; PPAR gamma; Rats; Receptors, N-Methyl-D-Aspartate; Rosiglitazone; Stroke; Thiazolidinediones

2007